To investigate the above speculation, the DR-BC cells were pretreated with 10 μmol/L of AMPK inhibitor compound C and 6 μmol/L ULK1 inhibitor SBI-0206965 for 24 h to inactivate AMPK-ULK1 signaling cascade, and the results showed that compound C decreased p-AMPK expression levels (Fig. 4c, d) and SBI-0206965 inhibited p-ULK1 (555) and p-ULK1 (757) expressions (Fig. 4e, f) in high-dose doxorubicin treated DR-BC cells. Here, ULK1 is linked to breast cancer.